Plain-English translation of NCT05953584 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help prevent strokes in young people with sickle cell disease who are at higher risk. Researchers will give participants this medication for one year and measure whether it helps slow down blood flow in the brain (which is a sign of stroke risk). The study also wants to make sure the medication is safe for children and teens to take.
Sickle cell disease can cause dangerous blood clots and changes in blood vessels that increase the risk of stroke in young people. While some treatments exist, researchers want to find new options that work well and are safe for this age group, especially for patients who cannot take or have not fully responded to current treatments.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily for 52 weeks (one year), taking two tablets of 200 mg each with a glass of water—with or without food. You will visit the clinic frequently for check-ups, blood tests, and ultrasound scans of your brain to see if the medication is working and to monitor for side effects. After the main year-long period, you have the option to continue in an extended 48-week phase if you and your doctor think it's helpful.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
India